New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration | Zendy

Young Gun Park | Zendy; Hyun Wook Rhu | Zendy; Seungbum Kang | Zendy; YoungJung Roh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration

Author(s) -

Young Gun Park,

Hyun Wook Rhu,

Seungbum Kang,

YoungJung Roh

Publication year - 2012

Publication title -

journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.818

H-Index - 40

eISSN - 2090-0058

pISSN - 2090-004X

DOI - 10.1155/2012/637316

Subject(s) - medicine , macular degeneration , regimen , clinical trial , vegf receptors , choroidal neovascularization , bevacizumab , ranibizumab , oncology , ophthalmology , chemotherapy

Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research